Study reveals agreement on symptoms as well as patient knowledge gaps, need for new treatments to focus on quality of life for serious women’s health infections
Newark, NJ, October 25, 2016 – Symbiomix, a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections, today announced that data recently presented at the International Society for Quality of Life Research 23rd Annual Conference in Copenhagen, Denmark are the results of a Symbiomix-sponsored study examining perspectives on bacterial vaginosis (BV) among clinicians and patients. Read more..
-
Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference
October 25, 2016 | Posted in Events, News
-
Symbiomix Therapeutics to Host Educational Awareness Reception on Bacterial Vaginosis at 19th Annual NPWH Premier Women’s Healthcare Conference
September 28, 2016 | Posted in Events, News
Nurse Practitioner Alisa Pascale, DNP, WHNP-BC, to present on bacterial vaginosis (BV)
Company to present three posters on BV disease state, antimicrobial activity of secnidazole/pharmacokinetic analyses of Solosec™, and clinical data summary of Solosec™ Read more
-
Symbiomix Therapeutics Accelerates Commercial Launch Preparation for Solosec™ Following Presentation of Results from Second Pivotal Trial at IDSOG
August 17, 2016 | Posted in Events, News
Company hires seasoned commercial executive Taunia Markvicka, PharmD, MBA, as Chief Commercial Officer.
FDA conditionally accepts proprietary name Solosec™.
Solosec™ launch targeted for 2H 2017 as the first and only single-dose oral therapy for BV, the most prevalent women’s health infection in the US.
Newark, NJ, August 17, 2016 – Symbiomix today announced it is accelerating plans for the commercial launch of Solosec™ Read more